Sandoz Inc. and Lupin Ltd. have agreed to pay a combined $6.7 million to exit multidistrict litigation accusing them of striking a deal with a Valeant Pharmaceuticals Corp. unit to delay launching their generic versions of the acne medication Solodyn, according to a pair of proposed deals Tuesday.